GlassScriptPhysician profile
Florentino E Palmon
NPI 1396836037
$3,329.17
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $371 · 2021: $762 · 2022: $621 · 2023: $503 · 2024: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $893.66 | 2019-2024 | Rocklatan, Simbrinza, Rhopressa |
| Allergan, INC. | $322.89 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $299.87 | 2019-2022 | |
| Dompe US, INC. | $296.42 | 2019-2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $279.49 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $218.36 | 2019-2023 | Cequa |
| Glaukos Corporation | $173.96 | 2019-2022 | |
| Abbvie INC. | $130.52 | 2022-2024 | |
| Ocular Therapeutix, INC. | $121.76 | 2019-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $101.19 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $93.26 | 2022-2024 | Miebo, Xiidra, Envista Mx60 Iol |
| Mallinckrodt Hospital Products INC. | $87.44 | 2021-2023 | Acthar |
| Thea Pharma INC. | $46.45 | 2022-2023 | Iyuzeh |
| Beaver-Visitec International, INC. | $42.33 | 2021 | |
| Aerie Pharmaceuticals, INC. | $40.75 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $26.28 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $24.49 | 2024 | Xdemvy |
| Recordati_rare_diseases_inc. | $24.47 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $20.61 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.53 | 2020 | |
| Biotissue Holdings INC. | $18.26 | 2022 | |
| Harrow Eye, LLC | $17.02 | 2024 | Vevye |
| Sight Sciences, INC. | $16.16 | 2021 | |
| Leadiant Biosciences, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florentino Palmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.